Active Pharmaceutical Ingredient Market

Active Pharmaceutical Ingredient Market Size, Growth by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC,Rx), Application (Diabetes, Oncology, CVD) - Global Forecasts to 2027

Report Code: PH 1262 Dec, 2022, by marketsandmarkets.com

The global Active Pharmaceutical Ingredient Market boasts a total value of $145.9 billion in 2022 and is projected to register a growth rate of 8.2% to reach a value of $216.4 billion by 2027. The production capacity expansions by pharmaceutical and biopharmaceutical players, the growing importance of generics, and technological advancements in API manufacturing are some of the major factors driving the growth of this market. However, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

Active Pharmaceutical Ingredient Market

To know about the assumptions considered for the study, Request for Free Sample Report

Active Pharmaceutical Ingredient Market Dynamics

Growth Drivers: Focus on precision medicine

  • Precision medicine considers the variability in the environment, genes, and lifestyle of each individual. With this approach, predicting prevention and treatment strategies for a particular disease in particular groups of people has become more accurate. The approach ensures that the therapeutic or preventive interventions are directed to patients in such a way that benefits are maximized and cost and complications are minimized.
  • Precision medicine is gaining increasing recognition from clinicians, healthcare systems, pharmaceutical companies, patients, and governments. Advances in precision medicine have already led to powerful discoveries and several new FDA-approved treatments that are tailored to the specific characteristics of individuals. Realizing the potential of precision medicine, in 2018, the US government launched the All of US research program to enroll 1 million or more volunteers and oversample communities that are underrepresented in research. The program will focus on finding breakthroughs in the field of precision medicine. The HHS Health Resources and Services Administration (HRSA) also awarded USD 21 million to 46 community health centers to support their participation in the program.
  • Under the focus area of precision medicine, oncology comes out at the top amongst all therapeutic areas. The objective while conducting clinical trials for such innovative drugs is to generate pharmacologically effective drug concentrations at the disease site while keeping minimal drug concentrations in rest of the body.

Growth Opportunities: Emerging biosimilars market

  • The rising incidence of various diseases, the increasing number of off-patent biologic drugs, positive outcomes in ongoing clinical trials for biosimilars, and the rising demand for biosimilars in different therapeutic applications (such as rheumatoid arthritis and blood disorders) are the major factors driving the growth of the biosimilars market. Biosimilars are generic versions of patented biologic drugs; hence, they do not need to comply with the stringent requirements of various regulatory authorities (making them cost-effective as compared to patented biologics). The expiration of patents and other intellectual property rights for originator biologics over the next decade is expected to open up opportunities for biosimilars to enter the market.

Restraints: Unfavorable drug price control policies

  • Most nations control pharmaceutical manufacturer prices, either directly (France and Italy) or indirectly (Germany and Japan), through restrictions on reimbursement or profits (UK). It is generally accepted that countries with rigorous price restrictions have lower drug prices than nations with laxer regulation (UK) or no regulation (US).
  • Pharmaceutical drug prices have been increasing gradually across the globe in the past few years. When it comes to drug prices the US is a major unregulated market. Although, various prominent countries have regulated drug prices. To limit spending on pharmaceuticals, governments of several countries induce price controls. However, revenue of pharmaceutical companies takes a hit due to such regulated drug prices. This in turn lead to a reduction in R&D spending and lower new molecular entities (NMEs) being developed per annum.
  • Since the bargaining power of API suppliers is low, price regulations of drug products will directly impact the prices of active pharmaceutical ingredients as well.

Challenges: Increasing penetration of counterfeit drugs

  • Falsified or fake medicines include ingredients of bad or toxic quality in the wrong dosage forms. According to the WHO, ~10% of all medicines are counterfeit. The incidence of falsification of medicines is reported to be around 1% (of all medicines) in countries that have superior laws and control over the supply of medicines. However, in low- and middle-income countries, the level of falsified medicines rises to around 50%.
  • The growing penetration of counterfeit drugs is resulting in revenue losses for authentic API manufacturers. The EU Intellectual Property Office (EUIPO) has estimated that the EU pharmaceutical industry loses the equivalent of nearly 7% in sales per year to counterfeit drugs, which amounts to USD 30.70 billion (EUR 26.9 billion) annually. Also, around 7,100 jobs are lost annually due to counterfeit medicines/falsified medicines in the region.
  • The European Falsified Medicines Directive (FMD) seeks to prevent falsified medicines from entering the legal supply chain in the European Union (EU). The EU focuses on strengthening safety and governing measures across Europe in fields such as APIs and excipients, safety features of medicines, supply chain and good distribution practices (GDPs), and internet sales.

The prescription drugs segment is expected to account for the largest share of the APIs market.

Based on the type of drug, the APIs market can be classified into two segments: prescription drugs and over-the-counter (OTC) drugs. The prescription drugs segment accounted for the largest share of the APIs market. Since the majority of the drugs are sold only with a doctor’s prescription, the demand for APIs for manufacturing such drugs is the highest. Rising innovator drugs can also be attributed to the growing demand for APIs in the prescription drug segment. Additionally, government initiatives to make drugs affordable and the rise of generics will attribute to the larger share of this segment.

The mammalian expression systems segment is expected to account for the largest share of the biotech APIs market

On the basis of the expression system, biotech APIs can be categorised into mammalian expression systems, microbial expression systems, yeast expression systems, insect expression systems, and other expression systems. As mammalian expression systems offer efficient protein folding and the highest level of post-translational modification, they account for the largest share in the biotech APIs market by expression system. Moreover, they are most suitable for human use.

Active Pharmaceutical Ingredient Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America is expected to account for the largest market size during the forecast period.

Geographically, the APIs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America dominated the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the presence of major pharmaceutical and biopharmaceutical manufacturing facilities, an increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures as well as the introduction of low-cost and generic versions of branded drugs.

The prominent players in this market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK).

Pfizer is one of the leading player in the market. The leading position of the company is largely attributed to its exhaustive product portfolio. The company has a strong brand image, which gives it a competitive edge over other players. In order to remain competitive and strengthen its market position, the company primarily focuses on adopting both organic and inorganic growth strategies, such as agreements, partnerships, collaborations, product approvals, and acquisitions.

Active Pharmaceutical Ingredient Market Report Scope

Report Metric

Details

Market Revenue in 2022

$145.9 billion

Estimated Value by 2027

$216.4 billion

Growth Rate

Poised to grow at a CAGR of 8.2%

Largest Share Segments

  • Prescription Drugs & Mammalian Expression Systems

Market Report Segmentation

Type, Potency, Type of Synthesis, Type of Drug, Therapeutic Application, and Region

Growth Drivers

  • Growing importance of generics
  • Increasing uptake of biopharmaceuticals
  • Growing focus on precision medicine
  • Technological advancements in API manufacturing
  • Increasing incidence of chronic diseases

Growth Opportunities
  • Emerging Biosimilars Market

Geographies covered

North America, Europe, APAC, MEA, and Latin America

Active Pharmaceutical Ingredient Market Report Segmentation

By Type

  • Innovative APIs
  • Generic APIS

By Potency

By Type of Synthesis

  • Synthetic APIs Market

Synthetic APIs, by Type

  • Innovative Synthetic APIs
  • Generic Synthetic APIs
  • Biotech APIs Market

Biotech APIs, by Type

  • Innovative Biotech APIs
  • Generic Biotech APIs

Biotech APIs, by Product

  • Monoclonal Antibodies
  • Hormones and Growth Factors
  • Cytokines
  • Fusion Proteins
  • Therapeutic Enzymes
  • Recombinant Vaccines
  • Blood Factors

Biotech APIs, by Expression System

  • Mammalian Expression Systems
  • Microbial Expression Systems
  • Yeast Expression Systems
  • Insect Expression Systems
  • Other Expression Systems

By Type of Drug

  • Prescription Drugs
  • Over-the-counter Drugs

By Therapeutic Application

  • Communicable Diseases
  • Oncology
  • Diabetes
  • Cardiovascular Diseases
  • Pain Management
  • Respiratory Diseases
  • Other Therapeutic Applications

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments:

  • In 2022, Pfizer entered into an agreement with Acuitas to deliver a lipid nanoparticle delivery system for use in mRNA vaccines such as COMIRNATY ((tozinameran) and therapeutics.
  • In 2022, Sanofi and IGM announced a strategic collaboration agreement to streamline and optimize the development and commercialization of IgM antibody agonists for oncology, immunology, and inflammation target.
  • In 2022, Boehringer Ingelheim and Mabgenesis collaborated to develop novel monoclonal antibodies for canine therapeutic treatments.
  • In 2021, Pfizer invested USD 68.5 million in in new state-of-the-art facility in Durham, NC, to further advance gene therapy capabilities.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 48)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 MARKET SEGMENTATION
           1.3.2 GEOGRAPHIC SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 52)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 5 MARKET SIZE ESTIMATION: DEMAND-SIDE ANALYSIS
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION 
    2.5 ASSUMPTIONS 
 
3 EXECUTIVE SUMMARY (Page No. - 60)
    FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022 VS. 2027 (USD BILLION)
    FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET SHARE, BY TYPE OF SYNTHESIS, 2021
    FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022 VS. 2027 (USD BILLION)
    FIGURE 10 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022 VS. 2027 (USD BILLION)
    FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENT MARKET SHARE, BY THERAPEUTIC APPLICATION, 2021
    FIGURE 12 GEOGRAPHICAL SNAPSHOT OF ACTIVE PHARMACEUTICAL INGREDIENT MARKET
 
4 PREMIUM INSIGHTS (Page No. - 65)
    4.1 ACTIVE PHARMACEUTICAL INGREDIENT MARKET OVERVIEW 
          FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
    4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE AND COUNTRY (2021) 
          FIGURE 14 INNOVATIVE APIS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
    4.3 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 15 ASIA PACIFIC TO WITNESS HIGHEST GROWTH IN FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 68)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Pharmaceutical and biopharmaceutical capacity expansion
                    5.2.1.2 Growing importance of generics
                                TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2021
                    5.2.1.3 Increasing uptake of biopharmaceuticals
                                TABLE 2 US: INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN 2021
                    5.2.1.4 Technological advancements in API manufacturing
                    5.2.1.5 Focus on precision medicine
                    5.2.1.6 Increasing incidence of chronic diseases
           5.2.2 RESTRAINTS
                    5.2.2.1 Complications during API manufacturing
                    5.2.2.2 Low profit margins and high manufacturing costs
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging biosimilars market
                                TABLE 3 US: INDICATIVE LIST OF BIOSIMILARS THAT GAINED REGULATORY APPROVAL (2021–2022)
                    5.2.3.2 Highly potent active pharmaceutical ingredients
                    5.2.3.3 Emerging markets
                    5.2.3.4 Emerging technologies/processes
           5.2.4 CHALLENGES
                    5.2.4.1 Increasing penetration of counterfeit drugs
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 17 MAJOR VALUE ADDED DURING MANUFACTURING
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 18 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.5 ECOSYSTEM ANALYSIS: ACTIVE PHARMACEUTICAL INGREDIENT MARKET 
          FIGURE 19 ECOSYSTEM ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENT MARKET
    5.6 PATENT ANALYSIS 
          FIGURE 20 PATENT APPLICATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS, JANUARY 2010–DECEMBER 2021
    5.7 KEY CONFERENCES AND EVENTS 
          TABLE 4 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022–2023
    5.8 TARIFF AND REGULATORY LANDSCAPE 
           5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.9 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 THREAT OF NEW ENTRANTS
           5.9.2 THREAT OF SUBSTITUTES
           5.9.3 BARGAINING POWER OF SUPPLIERS
           5.9.4 BARGAINING POWER OF BUYERS
           5.9.5 INTENSITY OF COMPETITIVE RIVALRY
    5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ACTIVE PHARMACEUTICAL INGREDIENTS
           5.10.2 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS
                     FIGURE 22 KEY BUYING CRITERIA FOR END USERS
    5.11 PRICING ANALYSIS 
           TABLE 9 IMPORTERS FOR ANTIBIOTICS (HS CODE – 2941)
           TABLE 10 EXPORTERS FOR ANTIBIOTICS (HS CODE – 2941)
           TABLE 11 IMPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE – 2934)
           TABLE 12 EXPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE – 2934)
           TABLE 13 IMPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE – 2937)
           TABLE 14 EXPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE – 2937)
    5.12 TRADE ANALYSIS 
           TABLE 15 TOP 10 IMPORTERS FOR ANTIBIOTICS (HS CODE – 2941)
           TABLE 16 TOP 10 EXPORTERS OF ANTIBIOTICS (HS CODE – 2941)
           TABLE 17 TOP 10 IMPORTERS OF NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE – 2934)
           TABLE 18 TOP 10 EXPORTERS OF NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE – 2934)
           TABLE 19 TOP 10 IMPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE – 2937)
           TABLE 20 TOP 10 EXPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE – 2937)
 
6 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (Page No. - 94)
    6.1 INTRODUCTION 
          TABLE 21 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2020–2027 (USD BILLION)
    6.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT) 
          TABLE 22 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2020–2027 (USD BILLION)
          TABLE 23 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2020–2027 (USD BILLION)
    6.3 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS 
           6.3.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVALS TO DRIVE MARKET
                    TABLE 24 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2020–2027 (USD BILLION)
                    TABLE 25 NORTH AMERICA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 26 EUROPE: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 27 ASIA PACIFIC: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 28 REST OF THE WORLD: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
    6.4 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS 
           6.4.1 GOVERNMENT INITIATIVES SUPPORTING ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH
                    TABLE 29 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2020–2027 (USD BILLION)
                    TABLE 30 NORTH AMERICA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 31 EUROPE: GENERIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 32 ASIA PACIFIC: GENERIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 33 REST OF THE WORLD: GENERIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
 
7 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY (Page No. - 102)
    7.1 INTRODUCTION 
          TABLE 34 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2020–2027 (USD BILLION)
    7.2 TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS 
           7.2.1 APPLICATION IN VARIOUS THERAPEUTIC AREAS TO SUPPORT MARKET GROWTH
                    TABLE 35 TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2020–2027 (USD BILLION)
                    TABLE 36 NORTH AMERICA: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 37 EUROPE: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 38 ASIA PACIFIC: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 39 REST OF THE WORLD: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
    7.3 HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS 
           7.3.1 INCREASING APPLICATION ACROSS RANGE OF THERAPEUTIC AREAS TO DRIVE MARKET
                    TABLE 40 HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2020–2027 (USD BILLION)
                    TABLE 41 NORTH AMERICA: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 42 EUROPE: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 43 ASIA PACIFIC: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 44 REST OF THE WORLD: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
 
8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF SYNTHESIS (Page No. - 109)
    8.1 INTRODUCTION 
          TABLE 45 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
    8.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT) 
          TABLE 46 APIs Market, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2020–2027 (USD BILLION)
          TABLE 47 CAPTIVE APIs Market, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
    8.3 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS 
          TABLE 48 SYNTHETIC APIs Market, BY REGION, 2020–2027 (USD BILLION)
          TABLE 49 NORTH AMERICA: SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
          TABLE 50 EUROPE: SYNTHETIC , BY COUNTRY, 2020–2027 (USD BILLION)
          TABLE 51 ASIA PACIFIC: SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
          TABLE 52 REST OF THE WORLD: SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
           8.3.1 SYNTHETIC APIs Market, BY TYPE
                    TABLE 53 SYNTHETIC APIs Market, BY TYPE, 2020–2027 (USD BILLION)
                    8.3.1.1 Innovative synthetic APIs
                               8.3.1.1.1 High value of innovative APIs to drive market
                                              TABLE 54 INNOVATIVE SYNTHETIC APIs Market, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 55 NORTH AMERICA: INNOVATIVE SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 56 EUROPE: INNOVATIVE SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 57 ASIA PACIFIC: INNOVATIVE SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 58 REST OF THE WORLD: INNOVATIVE SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.3.1.2 Generic synthetic APIs
                               8.3.1.2.1 Initiatives to promote penetration of generics to support market growth
                                              TABLE 59 GENERIC SYNTHETIC APIs Market, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 60 NORTH AMERICA: GENERIC SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 61 EUROPE: GENERIC SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 62 ASIA PACIFIC: GENERIC SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 63 REST OF THE WORLD: GENERIC SYNTHETIC APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
    8.4 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS 
          TABLE 64 BIOTECH APIs Market, BY REGION, 2020–2027 (USD BILLION)
          TABLE 65 NORTH AMERICA: BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
          TABLE 66 EUROPE: BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
          TABLE 67 ASIA PACIFIC: BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
          TABLE 68 REST OF THE WORLD: BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
           8.4.1 BIOTECH APIs Market, BY TYPE
                    TABLE 69 BIOTECH APIs Market, BY TYPE, 2020–2027 (USD BILLION)
                    8.4.1.1 Innovative biotech APIs
                               8.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive market
                                              TABLE 70 INNOVATIVE BIOTECH APIs Market, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 71 NORTH AMERICA: INNOVATIVE BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 72 EUROPE: INNOVATIVE BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 73 ASIA PACIFIC: INNOVATIVE BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 74 REST OF THE WORLD: INNOVATIVE BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.1.2 Generic biotech APIs
                               8.4.1.2.1 Increasing demand for biosimilar drugs due to cost-effectiveness to drive market
                                              TABLE 75 GENERIC BIOTECH APIs Market, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 76 NORTH AMERICA: GENERIC BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 77 EUROPE: GENERIC BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 78 ASIA PACIFIC: GENERIC BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 79 REST OF THE WORLD: GENERIC BIOTECH APIs Market, BY COUNTRY, 2020–2027 (USD BILLION)
           8.4.2 BIOTECH APIs Market, BY PRODUCT
                    TABLE 80 BIOTECH APIs Market, BY PRODUCT, 2020–2027 (USD BILLION)
                    8.4.2.1 Monoclonal antibodies
                               8.4.2.1.1 Growing applications of antibody-drug conjugates in treatment of cancer to drive growth
                                              TABLE 81 BIOTECH APIs Market FOR MONOCLONAL ANTIBODIES, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 82 NORTH AMERICA: BIOTECH APIs Market FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 83 EUROPE: BIOTECH APIs Market FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 84 ASIA PACIFIC: BIOTECH APIs Market FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 85 REST OF THE WORLD: BIOTECH APIs Market FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.2.2 Hormones and growth factors
                               8.4.2.2.1 Growing incidence of hormonal disorders to drive market
                                              TABLE 86 BIOTECH APIs Market FOR HORMONES AND GROWTH FACTORS, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 87 NORTH AMERICA: BIOTECH APIs Market FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 88 EUROPE: BIOTECH APIs Market FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 89 ASIA PACIFIC: BIOTECH APIs Market FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 90 REST OF THE WORLD: BIOTECH APIs Market FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.2.3 Cytokines
                               8.4.2.3.1 Interferons and interleukins boost immune system
                                              TABLE 91 BIOTECH APIs Market FOR CYTOKINES, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 92 NORTH AMERICA: BIOTECH APIs Market FOR CYTOKINES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 93 EUROPE: BIOTECH APIs Market FOR CYTOKINES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 94 ASIA PACIFIC: BIOTECH APIs Market FOR CYTOKINES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 95 REST OF THE WORLD: BIOTECH APIs Market FOR CYTOKINES, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.2.4 Fusion proteins
                               8.4.2.4.1 Growing applications of fusion proteins in biopharmaceuticals to drive market
                                              TABLE 96 BIOTECH APIs Market FOR FUSION PROTEINS, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 97 NORTH AMERICA: BIOTECH APIs Market FOR FUSION PROTEINS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 98 EUROPE: BIOTECH APIs Market FOR FUSION PROTEINS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 99 ASIA PACIFIC: BIOTECH APIs Market FOR FUSION PROTEINS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 100 REST OF THE WORLD: BIOTECH API Market FOR FUSION PROTEINS, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.2.5 Recombinant vaccines
                               8.4.2.5.1 Growing prevalence of infectious diseases to boost vaccine development
                                              TABLE 101 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 102 NORTH AMERICA: BIOTECH API Market FOR RECOMBINANT VACCINES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 103 EUROPE: BIOTECH API Market FOR RECOMBINANT VACCINES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 104 ASIA PACIFIC: BIOTECH API Market FOR RECOMBINANT VACCINES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 105 REST OF THE WORLD: BIOTECH API Market FOR RECOMBINANT VACCINES, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.2.6 Therapeutic enzymes
                               8.4.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive market
                                              TABLE 106 BIOTECH API Market FOR THERAPEUTIC ENZYMES, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 107 NORTH AMERICA: BIOTECH API Market FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 108 EUROPE: BIOTECH API Market FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 109 ASIA PACIFIC: BIOTECH API Market FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 110 REST OF THE WORLD: BIOTECH API Market FOR THERAPEUTIC ENZYMES, 2020–2027 (USD BILLION)
                    8.4.2.7 Blood factors
                               8.4.2.7.1 Growing incidence of hemophilia to drive market
                                              TABLE 111 BIOTECH API Market FOR BLOOD FACTORS, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 112 NORTH AMERICA: BIOTECH API Market FOR BLOOD FACTORS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 113 EUROPE: BIOTECH API Market FOR BLOOD FACTORS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 114 ASIA PACIFIC: BIOTECH API Market FOR BLOOD FACTORS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 115 REST OF THE WORLD: BIOTECH API Market FOR BLOOD FACTORS, 2020–2027 (USD BILLION)
           8.4.3 BIOTECH API Market, BY EXPRESSION SYSTEM
                    TABLE 116 BIOTECH API Market, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                    8.4.3.1 Mammalian expression systems
                               8.4.3.1.1 Ability to carry post-translational modifications to drive adoption
                                              TABLE 117 BIOTECH API Market FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 118 NORTH AMERICA: BIOTECH API Market FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 119 EUROPE: BIOTECH API Market FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 120 ASIA PACIFIC: BIOTECH API Market FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 121 REST OF THE WORLD: BIOTECH API Market FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.3.2 Microbial expression systems
                               8.4.3.2.1 High expression levels of proteins at low costs to drive market
                                              TABLE 122 BIOTECH API Market FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 123 NORTH AMERICA: BIOTECH API Market FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 124 EUROPE: BIOTECH API Market FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 125 ASIA PACIFIC: BIOTECH API Market FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 126 REST OF THE WORLD: BIOTECH API Market FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.3.3 Yeast expression systems
                               8.4.3.3.1 Efficient protein secretion, simple purification, and endotoxin-free products to boost demand
                                              TABLE 127 BIOTECH API Market FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 128 NORTH AMERICA: BIOTECH API Market FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 129 EUROPE: BIOTECH API Market FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 130 ASIA PACIFIC: BIOTECH API Market FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 131 REST OF THE WORLD: BIOTECH API Market FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.3.4 Insect expression systems
                               8.4.3.4.1 Efficient post-translational modifications to boost adoption
                                              TABLE 132 BIOTECH API Market FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION)
                                              TABLE 133 NORTH AMERICA: BIOTECH API Market FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 134 EUROPE: BIOTECH API Market FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 135 ASIA PACIFIC: BIOTECH API Market FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                              TABLE 136 REST OF THE WORLD: BIOTECH API Market FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                    8.4.3.5 Other expression systems
                                      TABLE 137 BIOTECH API Market FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION)
                                      TABLE 138 NORTH AMERICA: BIOTECH API Market FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                      TABLE 139 EUROPE: BIOTECH API Market FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                      TABLE 140 ASIA PACIFIC: BIOTECH API Market FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
                                      TABLE 141 REST OF THE WORLD: BIOTECH API Market FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION)
 
9 API Market, BY TYPE OF DRUG (Page No. - 162)
    9.1 INTRODUCTION 
          TABLE 142 API Market, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
    9.2 PRESCRIPTION DRUGS 
           9.2.1 GROWING DISEASE PREVALENCE TO SUPPORT MARKET GROWTH
                    TABLE 143 PRESCRIPTION DRUGS MARKET, BY REGION, 2020–2027 (USD BILLION)
                    TABLE 144 NORTH AMERICA: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 145 EUROPE: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 146 ASIA PACIFIC: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 147 REST OF THE WORLD: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
    9.3 OVER-THE-COUNTER DRUGS 
           9.3.1 INCREASED SALES OF OTC DRUGS DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS
                    TABLE 148 OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2020–2027 (USD BILLION)
                    TABLE 149 NORTH AMERICA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 150 EUROPE: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 151 ASIA PACIFIC: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
                    TABLE 152 REST OF THE WORLD: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
 
10 API Market, BY THERAPEUTIC APPLICATION (Page No. - 170)
     10.1 INTRODUCTION 
             TABLE 153 MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
     10.2 COMMUNICABLE DISEASES 
             10.2.1 LARGEST AND FASTEST-GROWING MARKET SEGMENT
                        TABLE 154 API MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2020–2027 (USD BILLION)
                        TABLE 155 NORTH AMERICA: API MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 156 EUROPE: API MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 157 ASIA PACIFIC: API MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 158 REST OF THE WORLD: API MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
     10.3 ONCOLOGY 
             10.3.1 INCREASING SPENDING ON CANCER MEDICATION TO SUPPORT MARKET GROWTH
                        TABLE 159 API MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD BILLION)
                        TABLE 160 NORTH AMERICA: API MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 161 EUROPE: API MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 162 ASIA PACIFIC: API MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 163 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD BILLION)
     10.4 DIABETES 
             10.4.1 HIGH PREVALENCE OF DIABETES TO DRIVE MARKET
                        TABLE 164 MARKET FOR DIABETES, BY REGION, 2020–2027 (USD BILLION)
                        TABLE 165 NORTH AMERICA: MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 166 EUROPE: MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 167 ASIA PACIFIC: MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 168 REST OF THE WORLD: MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD BILLION)
     10.5 CARDIOVASCULAR DISEASES 
             10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES
                        TABLE 169 MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD BILLION)
                        TABLE 170 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 171 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 172 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 173 REST OF THE WORLD: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
     10.6 PAIN MANAGEMENT 
             10.6.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO PROPEL MARKET
                        TABLE 174 MARKET FOR PAIN MANAGEMENT, BY REGION, 2020–2027 (USD BILLION)
                        TABLE 175 NORTH AMERICA: MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 176 EUROPE: MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 177 ASIA PACIFIC: MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 178 REST OF THE WORLD: MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020–2027 (USD BILLION)
     10.7 RESPIRATORY DISEASES 
             10.7.1 HIGH PREVALENCE OF RESPIRATORY DISEASES TO SUPPORT MARKET GROWTH
                        TABLE 179 MARKET FOR RESPIRATORY DISEASES, BY REGION, 2020–2027 (USD BILLION)
                        TABLE 180 NORTH AMERICA: MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 181 EUROPE: MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 182 ASIA PACIFIC: MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
                        TABLE 183 REST OF THE WORLD: MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020–2027 (USD BILLION)
     10.8 OTHER THERAPEUTIC APPLICATIONS 
             TABLE 184 MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD BILLION)
             TABLE 185 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
             TABLE 186 EUROPE: MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
             TABLE 187 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
             TABLE 188 REST OF THE WORLD: MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
 
11 MARKET, BY REGION (Page No. - 190)
     11.1 INTRODUCTION 
             TABLE 189 MARKET, BY REGION, 2020–2027 (USD BILLION)
     11.2 NORTH AMERICA 
             FIGURE 23 NORTH AMERICA: MARKET SNAPSHOT
             TABLE 190 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
             TABLE 191 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 192 NORTH AMERICA: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 USD BILLION)
             TABLE 193 NORTH AMERICA: SYNTHETIC MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 194 NORTH AMERICA: BIOTECH MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 195 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
             TABLE 196 NORTH AMERICA: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
             TABLE 197 NORTH AMERICA: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
             TABLE 198 NORTH AMERICA: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
             TABLE 199 NORTH AMERICA: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.2.1 US
                        11.2.1.1 Largest market for active pharmaceutical ingredients
                                      TABLE 200 US: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 201 US: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 202 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 203 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 204 US: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 205 US: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 206 US: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 207 US: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 208 US: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.2.2 CANADA
                        11.2.2.1 Growing pharmaceutical manufacturing to support market growth
                                      TABLE 209 CANADA: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 210 CANADA: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 211 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 212 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 213 CANADA: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 214 CANADA: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 215 CANADA: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 216 CANADA: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 217 CANADA: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
     11.3 EUROPE 
             TABLE 218 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
             TABLE 219 EUROPE: MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 220 EUROPE: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
             TABLE 221 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 222 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 223 EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
             TABLE 224 EUROPE: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
             TABLE 225 EUROPE: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
             TABLE 226 EUROPE: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
             TABLE 227 EUROPE: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.3.1 GERMANY
                        11.3.1.1 Leading country in terms of infrastructure and competency for R&D
                                      TABLE 228 GERMANY: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 229 GERMANY: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 230 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 231 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 232 GERMANY: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 233 GERMANY: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 234 GERMANY: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 235 GERMANY: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 236 GERMANY: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.3.2 FRANCE
                        11.3.2.1 Healthy pharmaceutical production to support API demand
                                      TABLE 237 FRANCE: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 238 FRANCE: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 239 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 240 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 241 FRANCE: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 242 FRANCE: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 243 FRANCE: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 244 FRANCE: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 245 FRANCE: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.3.3 UK
                        11.3.3.1 Rising government investments to drive market
                                      TABLE 246 UK: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 247 UK: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 248 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 249 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 250 UK: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 251 UK: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 252 UK: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 253 UK: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 254 UK: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.3.4 ITALY
                        11.3.4.1 Growing investment in API production to support market growth
                                      TABLE 255 ITALY: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 256 ITALY: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 257 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 258 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 259 ITALY: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 260 ITALY: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 261 ITALY: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 262 ITALY: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 263 ITALY: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increase in generic drug manufacturing capacity to propel demand for APIs
                                      TABLE 264 SPAIN: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 265 SPAIN: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 266 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 267 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 268 SPAIN: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 269 SPAIN: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 270 SPAIN: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 271 SPAIN: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 272 SPAIN: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.3.6 HUNGARY
                        11.3.6.1 Rising incidence of chronic diseases to propel market growth
                                      TABLE 273 HUNGARY: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 274 HUNGARY: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 275 HUNGARY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 276 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 277 HUNGARY: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 278 HUNGARY: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 279 HUNGARY: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 280 HUNGARY: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 281 HUNGARY: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.3.7 REST OF EUROPE
                        TABLE 282 REST OF EUROPE: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 283 REST OF EUROPE: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                        TABLE 284 REST OF EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 285 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 286 REST OF EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                        TABLE 287 REST OF EUROPE: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                        TABLE 288 REST OF EUROPE: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                        TABLE 289 REST OF EUROPE: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                        TABLE 290 REST OF EUROPE: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
     11.4 ASIA PACIFIC 
             FIGURE 24 ASIA PACIFIC: MARKET SNAPSHOT
             TABLE 291 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
             TABLE 292 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 293 ASIA PACIFIC: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
             TABLE 294 ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 295 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 296 ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
             TABLE 297 ASIA PACIFIC: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
             TABLE 298 ASIA PACIFIC: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
             TABLE 299 ASIA PACIFIC: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
             TABLE 300 ASIA PACIFIC: MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.4.1 JAPAN
                        11.4.1.1 Presence of large pharmaceutical companies to propel market
                                      TABLE 301 JAPAN: MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 302 JAPAN: MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 303 JAPAN: SYNTHETIC APIs Market, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 304 JAPAN: BIOTECH APIs Market, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 305 JAPAN: BIOTECH APIs Market, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 306 JAPAN: BIOTECH APIs Market, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 307 JAPAN: MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 308 JAPAN: MARKET, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 309 JAPAN: INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.4.2 CHINA
                        11.4.2.1 Government policies to increase medicine access and affordability to support market growth
                                      TABLE 310 CHINA: Market, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 311 CHINA: Market, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 312 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 313 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 314 CHINA: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 315 CHINA: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 316 CHINA: Market, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 317 CHINA: Market, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 318 CHINA: Market, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.4.3 INDIA
                        11.4.3.1 Leading producer of generics
                                      TABLE 319 INDIA: Market, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 320 INDIA: Market, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 321 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 322 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 323 INDIA: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 324 INDIA: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 325 INDIA: Market, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 326 INDIA: Market, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 327 INDIA: Market, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.4.4 SOUTH KOREA
                        11.4.4.1 Rising annual drug exports to drive market
                                      TABLE 328 SOUTH KOREA: Market, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 329 SOUTH KOREA: Market, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 330 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 331 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 332 SOUTH KOREA: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 333 SOUTH KOREA: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 334 SOUTH KOREA: Market, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 335 SOUTH KOREA: Market, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 336 SOUTH KOREA: Market, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.4.5 REST OF ASIA PACIFIC
                        TABLE 337 REST OF ASIA PACIFIC: Market, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 338 REST OF ASIA PACIFIC: Market, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                        TABLE 339 REST OF ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 340 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 341 REST OF ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                        TABLE 342 REST OF ASIA PACIFIC: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                        TABLE 343 REST OF ASIA PACIFIC: Market, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                        TABLE 344 REST OF ASIA PACIFIC: Market, BY POTENCY, 2020–2027 (USD BILLION)
                        TABLE 345 REST OF ASIA PACIFIC: Market, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
     11.5 REST OF THE WORLD 
             TABLE 346 REST OF THE WORLD: Market, BY COUNTRY, 2020–2027 (USD BILLION)
             TABLE 347 REST OF THE WORLD: Market, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 348 REST OF THE WORLD: Market, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
             TABLE 349 REST OF THE WORLD: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 350 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
             TABLE 351 REST OF THE WORLD: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
             TABLE 352 REST OF THE WORLD: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
             TABLE 353 REST OF THE WORLD: Market, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
             TABLE 354 REST OF THE WORLD: Market, BY POTENCY, 2020–2027 (USD BILLION)
             TABLE 355 REST OF THE WORLD: Market, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.5.1 ISRAEL
                        11.5.1.1 Financial support by government to drive market
                                      TABLE 356 ISRAEL: Market, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 357 ISRAEL: Market, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                                      TABLE 358 ISRAEL: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 359 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                                      TABLE 360 ISRAEL: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                                      TABLE 361 ISRAEL: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                                      TABLE 362 ISRAEL: Market, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                                      TABLE 363 ISRAEL: Market, BY POTENCY, 2020–2027 (USD BILLION)
                                      TABLE 364 ISRAEL: Market, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
             11.5.2 OTHER COUNTRIES
                        TABLE 365 OTHER COUNTRIES: Market, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 366 OTHER COUNTRIES: Market, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
                        TABLE 367 OTHER COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 368 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
                        TABLE 369 OTHER COUNTRIES: MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
                        TABLE 370 OTHER COUNTRIES: MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
                        TABLE 371 OTHER COUNTRIES: Market, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
                        TABLE 372 OTHER COUNTRIES: Market, BY POTENCY, 2020–2027 (USD BILLION)
                        TABLE 373 OTHER COUNTRIES: Market, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 276)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 25 KEY DEVELOPMENTS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2019–2022
     12.3 MARKET SHARE ANALYSIS 
             FIGURE 26 Market SHARE ANALYSIS, BY KEY PLAYER, 2021
             TABLE 374 Market: DEGREE OF COMPETITION
     12.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2019–2021
     12.5 COMPANY EVALUATION QUADRANT 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 28 Market: COMPANY EVALUATION QUADRANT, 2021
     12.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 29 Market: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021
     12.7 REGIONAL FOOTPRINT OF COMPANIES 
             TABLE 375 REGIONAL FOOTPRINT OF COMPANIES IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET (2021)
     12.8 COMPETITIVE SCENARIO 
             TABLE 376 KEY PRODUCT LAUNCHES
             TABLE 377 KEY DEALS
             TABLE 378 OTHER KEY DEVELOPMENTS
 
13 COMPANY PROFILES (Page No. - 288)
     13.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             13.1.1 PFIZER INC.
                        TABLE 379 PFIZER INC.: COMPANY OVERVIEW
                        FIGURE 30 PFIZER, INC.: COMPANY SNAPSHOT (2021)
             13.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
                        TABLE 380 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
                        FIGURE 31 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
             13.1.3 DIVI’S LABORATORIES LIMITED
                        TABLE 381 DIVI’S LABORATORIES LIMITED: COMPANY OVERVIEW
                        FIGURE 32 DIVI’S LABORATORIES LIMITED: COMPANY SNAPSHOT (2021)
             13.1.4 VIATRIS INC.
                        TABLE 382 VIATRIS INC.: COMPANY OVERVIEW
                        FIGURE 33 VIATRIS INC.: COMPANY SNAPSHOT (2021)
             13.1.5 NOVARTIS AG
                        TABLE 383 NOVARTIS AG: COMPANY OVERVIEW
                        FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2021)
             13.1.6 SANOFI
                        TABLE 384 SANOFI: COMPANY OVERVIEW
                        FIGURE 35 SANOFI: COMPANY SNAPSHOT (2021)
             13.1.7 BOEHRINGER INGELHEIM
                        TABLE 385 BOEHRINGER INGELHEIM: COMPANY OVERVIEW
                                                FIGURE 36 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2021)
             13.1.8 BRISTOL-MYERS SQUIBB
                        TABLE 386 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW
                        FIGURE 37 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2021)
             13.1.9 ELI LILLY AND COMPANY
                        TABLE 387 ELI LILLY AND COMPANY: COMPANY OVERVIEW
                        FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2021)
             13.1.10 GLAXOSMITHKLINE PLC
                        TABLE 388 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
                        FIGURE 39 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2021)
             13.1.11 MERCK & CO., INC.
                        TABLE 389 MERCK & CO., INC.: COMPANY OVERVIEW
                        FIGURE 40 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
             13.1.12 ABBVIE INC.
                        TABLE 390 ABBVIE INC.: COMPANY OVERVIEW
                        FIGURE 41 ABBVIE INC.: COMPANY SNAPSHOT (2021)
             13.1.13 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 391 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 42 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
             13.1.14 ASTRAZENECA
                        TABLE 392 ASTRAZENECA: COMPANY OVERVIEW
                        FIGURE 43 ASTRAZENECA: COMPANY SNAPSHOT (2021)
             13.1.15 DR. REDDY’S LABORATORIES LTD.
                        TABLE 393 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW
                        FIGURE 44 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2021)
             13.1.16 SUN PHARMACEUTICAL INDUSTRIES LTD.
                        TABLE 394 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
                        FIGURE 45 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
             13.1.17 CIPLA INC.
                        TABLE 395 CIPLA INC.: COMPANY OVERVIEW
                        FIGURE 46 CIPLA INC.: COMPANY SNAPSHOT (2021)
             13.1.18 AUROBINDO PHARMA
                        TABLE 396 AUROBINDO PHARMA: COMPANY OVERVIEW
                        FIGURE 47 AUROBINDO PHARMA LTD.: COMPANY SNAPSHOT (2021)
             13.1.19 EVONIK INDUSTRIES AG
                        TABLE 397 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
                        FIGURE 48 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 API PHARMA TECH
             13.2.2 BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD.
             13.2.3 SREEPATHI PHARMACEUTICALS LIMITED
             13.2.4 SHILPA MEDICARE LIMITED
 
14 APPENDIX (Page No. - 370)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

The study involved four major activities in estimating the current size of the global APIs market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary sources referred for this research study include publications from government sources, such as the World Health Organization (WHO), U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), International Society for Pharmaceutical Engineering (ISPE), Parenteral Drug Association (PDA), BioPharm International, and the National Center for Biotechnology Information (NCBI). Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines & research journals; press releases; and trade, business, and professional associations, among others. Secondary data was collected and analyzed to arrive at the overall size of the global active pharmaceutical ingredients market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global APIs market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from biopharma & pharma companies, clinical laboratories, and academic & research institutes; and purchase managers in healthcare provider organizations) and supply side (such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners, among others) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 70% and 30% of primary interviews were conducted with the supply side and demand side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews. A breakup is provided below:

Active Pharmaceutical Ingredients Market Size, and Share

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Active Pharmaceutical Ingredient Market Size Estimation

The revenue-based approach individually for instrument and consumable segments was used to estimate the global market size of the APIs market.

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global APIs market on the basis of type, potency, type of synthesis, type of drug, therapeutic application, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as partnerships, agreements, collaborations, joint ventures, alliances, mergers & acquisitions, approvals, expansions, and R&D activities in the global APIs market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs.

The following customization options are available for this report.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
Report Code
PH 1262
Published ON
Dec, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Active Pharmaceutical Ingredient Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback